Urothelial Carcinoma

According to the American Urological Association, 72.5% of urologists used Advanced Practice Providers in their practice and these healthcare providers performed a variety of procedures such as a cystoscopy (procedure examining bladder lining), which assists in the diagnosis of bladder cancer. Evidence shows patients have demonstrated a growing acceptance of APPs in urology practice settings.

Researchers identified being Black and of the female gender as the strongest predictors of late-stage diagnosis.

Results suggest potential for better use of precision medicine approaches.

A presentation at the 2021 American Society of Clinical Oncology meeting earlier this month reviewed recent findings from trials investigating the treatment of urothelial cancer.

A large proportion of patients with muscle-invasive bladder cancer responded to transurethral resection of bladder tumor and a drug cocktail that included gemcitabine, cisplatin and Opdivo (nivolumab).

Tumors glow pink under blue light.

A virtual summit on urothelial cancers is scheduled for October.

Oncology Analytics senior vice president Laura Bobolt discusses the new indication for Trodelvy and other matters.

The antibody-conjugate is also approved as a treatment for metastatic triple negative breast cancer.

As hearings of the FDA panel have shown, once a drug is approved and in clinical guidelines, pulling it from the market is not so simple, even if later trials do not confirm phase 2 results.

Drug would mean a nonsurgical treatment option for people with upper tract urothelial cancer.

COVID-19 vaccine is safe — and more than a little advisable — for people with urothelial cancer, says a clinical pharmacist at the VA Pittsburgh Healthcare System.

The advent of checkpoint inhibitors has altered the treatment landscape in urothelial bladder cancer, said Arlene O. Siefker-Radtke, MD, during last week’s NCCN Conference.

After accelerated approval, both drugs fall short of overall survival endpoint. They will stay on the market for other indications.

New drug may be a treatment option for people with the sixth most common type of cancer.

NCI Director Norman Sharpless discussed deferred care, missed screening and his future at the institute in an interview with Managed Healthcare Executive.

Adjustments to payment models are beginning to take social determinants into account.

Financial Toxicity is a growing concern for many cancer patients and caregivers, and with the continued rise in treatment costs, it can no longer be ignored.